South San Francisco-based pharmaceutical company Titan Pharmaceuticals, Inc. has developed a novel long-term drug delivery platform called ProNeura. The company's therapeutic products specifically cater to individuals suffering from chronic diseases. Its Probuphine implant has already been approved for use in the United States, Canada, and the European Union for maintenance treatment of opioid use disorder in clinically stable patients. Titan Pharmaceuticals has also developed TP-2021, a combination medication utilizing ProNeura technology to treat chronic pruritus, a severe skin condition characterized by itching lasting over six weeks. In addition, the company has programs in place for the prevention of opioid relapse through its Nalmefene implant program, as well as novel preventative therapeutics, including a contraceptive for women and adolescent girls through a single ProNeura implant. Titan Pharmaceuticals, Inc. was founded in 1992.